Combination therapy in type 2 diabetes: the role of repaglinide.
Wollongong, New South Wales, Australia.
R
R
Moses
D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007336:Insulin, Isophane / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D002219:Carbamates; D002839:Chromans; D007004:Hypoglycemic Agents; D010880:Piperidines; D013844:Thiazoles; D045162:Thiazolidinediones; D007336:Insulin, Isophane; C072379:repaglinide; D008687:Metformin; D000077288:Troglitazone